<?xml version="1.0"?><?xml-stylesheet type="text/xsl" href="../../web/xslt/drug-table.xslt"?><drug name = "ruxolitinib tab">
<dose><value>10</value>
<value>20</value>
<value>15</value>
<value>5</value>
<value>25</value>
</dose><route><value>PO</value>
</route><form><value>tab</value>
</form><drugname><value>ruxolitinib tab</value>
</drugname><strength><value>10 mg</value>
<value>15 mg</value>
<value>5 mg</value>
</strength><frequency><value>BID</value>
<value>DAILY</value>
</frequency><instruction></instruction><volume></volume><units><value>mg</value>
</units><additionalnotes><value>Recommended for end-stage renal disease, administered after each hemodialysis.</value>
</additionalnotes><population><value>ADULT</value>
</population><indicationprn></indicationprn><backgroundinformation><value>http://intraweb01.albertahealthservices.ca/Pharmacy/AHS_FORMULARY/search_details.aspx?id=6125</value>
<value>http://intraweb01.albertahealthservices.ca/Pharmacy/AHS_FORMULARY/search_details.aspx?id=6126</value>
<value>http://intraweb01.albertahealthservices.ca/Pharmacy/AHS_FORMULARY/search_details.aspx?id=6124</value>
</backgroundinformation><prninformation></prninformation><ahsformularystatus><value>Formulary with Restrictions.</value>
</ahsformularystatus><ahfsname><value>Antineoplastic Agents</value>
</ahfsname><highalert><value>YES</value>
</highalert><maximumprndose></maximumprndose><din><value>02434814</value>
<value>02388014</value>
<value>02388006</value>
</din><type><value>Medication/IV Therapy</value>
</type></drug>